In short
This article discusses the ongoing clinical trials of AZD0780, a new drug being investigated for the treatment of dyslipidemia. Dyslipidemia is a condition characterized by abnormal levels of lipids (fats) in the blood, which can increase the risk of cardiovascular diseases. The trials aim to evaluate the efficacy, safety, and tolerability of AZD0780 in lowering low-density lipoprotein cholesterol (LDL-C) levels in adults aged 18 to 75 with dyslipidemia.
At a glance
- Drug Name
- AZD0780
- Condition Studied
- Dyslipidemia
- Main Objective
- Evaluate effect on LDL-C levels
- Study Design
- Phase IIb, multicenter, randomized, double-blind, placebo-controlled
- Participant Age Range
- 18 to 75 years
- Treatment Duration
- Up to 87 days
- Key Inclusion Criteria
- Specific LDL-C levels, on statin therapy
- Key Exclusion Criteria
- Severe medical conditions, recent cardiovascular events
- Primary Endpoint
- Percent change in LDL-C at Week 12
- Secondary Endpoints
- Effects on other lipid parameters, safety, tolerability
What is AZD0780?
AZD0780 is a new drug being developed by AstraZeneca to treat dyslipidemia, a condition characterized by abnormal levels of lipids (fats) in the blood. The drug's full chemical name is 1-[6-[[(1S,3S)-3-[[5-(DIFLUOROMETHOXY)PYRIMIDIN-2-YL]AMINO]CYCLOPENTYL]AMINO]PYRIDIN-3-YL]PYRIDIN-2-ONE, but it's commonly referred to as AZD0780.
How does AZD0780 work?
While the exact mechanism of action is not fully described in the provided information, AZD0780 is designed to lower levels of low-density lipoprotein cholesterol (LDL-C) in the blood. LDL-C is often referred to as "bad cholesterol" because high levels can lead to the buildup of plaque in your arteries, increasing the risk of heart disease and stroke.
What condition does AZD0780 treat?
AZD0780 is being developed to treat dyslipidemia. Dyslipidemia refers to abnormal levels of lipids (fats) in the blood. A common form of dyslipidemia is hypercholesterolemia, which is characterized by high levels of LDL cholesterol. This condition is a major risk factor for cardiovascular disease (CVD), including conditions like ischemic heart disease and ischemic stroke. CVD is a leading cause of death globally and significantly contributes to disability.
Current Research on AZD0780
AZD0780 is currently being studied in a Phase IIb clinical trial. This is a crucial stage in drug development where researchers are testing different doses of the drug to determine its effectiveness, safety, and tolerability in patients with dyslipidemia.
Who can participate in the study?
The study is looking for participants who meet the following criteria:
- Men and women between 18 and 75 years old
- Have a fasting LDL-C level between 70 mg/dL (1.8 mmol/L) and 190 mg/dL (4.9 mmol/L)
- Have been taking a moderate or high-intensity statin (a type of cholesterol-lowering medication) for at least 2 months
- Have a body mass index of 19.0 kg/m² or higher
There are also several conditions that would exclude someone from participating, such as certain heart conditions, kidney problems, or uncontrolled high blood pressure.
What does the study involve?
The study is designed as a randomized, double-blind, placebo-controlled trial. This means that:
- Participants will be randomly assigned to receive either AZD0780 or a placebo (a substance with no active drug)
- Neither the participants nor the researchers will know who is receiving the actual drug and who is receiving the placebo
- The study will last for 12 weeks
- Researchers will measure the change in LDL-C levels from the start of the study to the end
- Other measurements will include changes in other types of cholesterol and fats in the blood, as well as markers of inflammation
Potential Benefits and Risks
The potential benefit of participating in this study is the possibility of lowering your LDL cholesterol levels, which could reduce your risk of heart disease. However, as with any experimental drug, there may be unknown risks or side effects. The study will closely monitor participants' health and safety throughout the trial.
It's important to note that this drug is still in the testing phase, and more research is needed to fully understand its effectiveness and safety profile. If you're interested in participating in this or similar clinical trials, you should discuss it with your healthcare provider to determine if it's appropriate for your individual situation.